SCHEMBL5436760

SCHEMBL5436760

COc1ccc(N(N)Cc2ccc(C#N)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.54
MAOB P27338 1/20 0.54
SNCA P37840 1/20 0.49
CYP19A1 P11511 5/20 0.44
STS P08842 1/20 0.43
PYCR1 P32322 1/20 0.43
AOC3 Q16853 2/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
CYP2A6 P11509 1/20 0.42
LOXL2 Q9Y4K0 1/20 0.42
VNN1 O95497 1/20 0.41
APLNR P35414 1/20 0.41
NR3C1 P04150 1/20 0.40
PGR P06401 1/20 0.40
KDR P35968 1/20 0.40
CACNA1G O43497 1/20 0.40
CACNA1B Q00975 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5991163 1.00 MAOA (0.54) MAOAMAOBSNCACYP19A1STS
SCHEMBL5992333 0.87 LOXL2 (0.54) CYP19A1STSPOLBCYP2A6LOXL2
SCHEMBL6799479 0.82 CYP19A1 (0.50) MAOAMAOBSNCACYP19A1POLB
SCHEMBL5991160 0.82 CYP2A6 (0.55) CYP19A1CYP2A6LOXL2
SCHEMBL12014951 0.82 ACHE (0.52) PYCR1AOC3MAPTAPLNR
SCHEMBL3140679 0.81 MEN1 (0.49) MAOBPYCR1AOC3MAPTAPLNR
SCHEMBL9145895 0.81 BCL2A1 (0.55) PYCR1AOC3APLNR
SCHEMBL12656069 0.81 AOC3 (0.45) PYCR1AOC3APLNR
SCHEMBL5992113 0.81 CYP19A1 (0.54) CYP19A1STSAOC3CACNA1GCACNA1B
SCHEMBL11052720 0.80 LTA4H (0.53) AOC3APLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8476455-B2 1-N-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them LABORATOIRE THERAMEX (MC) 2013-07-02 US disclosed
CN-100390151-C 1-N-phenylamino-1h-imidazole derivatives as aromatase inhibitors THERAMEX (MC) 2008-05-28 CN disclosed
US-20070112009-A1 1-N-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them LABORATOIRE THERAMEX (MC) 2007-05-17 US disclosed
EP-1694650-A1 1-N-PHENYL-AMINO-1H-IMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LABORATOIRE THERAMEX (MC) 2006-08-30 EP disclosed
EP-1572665-B1 1-N-PHENYLAMINO-1H-IMIDAZOLE DERIVATIVES AS AROMATASE INHIBITORS THERAMEX (MC) 2006-05-03 EP disclosed
CN-1720235-A 1-N-phenylamino-1h-imidazole derivatives as aromatase inhibitors THERAMEX (MC) 2006-01-11 CN disclosed
EP-1572665-A2 1-N-PHENYLAMINO-1H-IMIDAZOLE DERIVATIVES AS AROMATASE INHIBITORS LABORATOIRE THERAMEX (MC) 2005-09-14 EP disclosed
WO-2005058842-A1 1-N-PHENYL-AMINO-1H-IMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LABORATOIRE THERAMEX (MC) 2005-06-30 WO disclosed
EP-1544195-A1 1-N-phenyl-amino- 1H-imidazole derivatives and pharmaceutical compositions containing them LABORATOIRE THERAMEX (MC) 2005-06-22 EP disclosed
WO-2004054983-A2 1-N-PHENYLAMINO-1H-IMIDAZOLE DERIVATIVES AS AROMATASE INHIBITORS LABORATOIRE THERAMEX (MC) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112009-A1 1-N-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them H1-0, H1-5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MAOA 284/4885MAOB 171/4885SNCA 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.